Pacira Pharmaceuticals buy JPMorgan Chase & Co.
Start price
07.03.24
/
50%
€28.20
Target price
07.03.25
€41.38
Performance (%)
-14.89%
Price
26.04.24
€24.00
Summary
This prediction is currently active. The prediction for Pacira Pharmaceuticals disappoints with a performance of -14.89%. This prediction currently runs until 07.03.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | -0.826% | -0.826% |
| iShares Core DAX® | 2.594% | -1.861% |
| iShares Nasdaq 100 | 3.553% | -2.064% |
| iShares Nikkei 225® | 0.687% | -8.704% |
| iShares S&P 500 | 2.209% | -1.988% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat